title: Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients.
abstract: OBJECTIVE
  Hematological toxicity and oxidative stress are common in cancer patients. Antioxidant supplementation has been shown to decrease oxidative stress, but there is still controversy on this topic. The aim of this study was to determine the effect of antioxidant supplementation on oxidative stress, hematological toxicity, and quality of life (QoL) in cervical cancer patients.
  
  
  METHODS
  Randomized, single-blinded controlled trial in women with cervical cancer treated with radiotherapy and chemotherapy with cisplatin. Subjects were randomly assigned to receive antioxidant supplement or placebo supplement. Plasma concentrations of malondialdehyde, free carbonyls, and blood biometry were measured. EORTC quality of life questionnaire was applied before and after oncology treatment. Student's t test for independent samples and X (2) for categorical variables were performed.
  
  
  RESULTS
  One hundred three patients were randomly assigned to receive treatment with antioxidants 49 (48 %) or placebo 54 (52.40 %). At the end of the oncology treatment, hemoglobin levels were maintained, and global QoL was better only in the supplemented group (p < 0.025).
  
  
  CONCLUSIONS
  Antioxidant supplementation in patients treated with chemotherapy and radiotherapy apparently decreased oxidative stress, maintained hemoglobin levels, and improved QoL; however, more studies are needed to study the long-term effect of this intervention.
authors.affiliation: Servicio de Oncología, Hospital General de México, pabellón 111, Doctor Balmis No.148, Col. Doctores. Del. Cuauhtémoc, 06726, Mexico D. F., Mexico. vanessafuchs@hotmail.com
authors.forename: Vanessa
authors.initials: V
authors.lastname: Fuchs-Tarlovsky
authors.forename: María Amanda Casillas
authors.initials: MA
authors.lastname: Rivera
authors.forename: Karolina Alvarez
authors.initials: KA
authors.lastname: Altamirano
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Lopez-Alvarenga
authors.forename: Guillermo Manuel
authors.initials: GM
authors.lastname: Ceballos-Reyes
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology*; D059248:Chemoradiotherapy / Q000379:methods; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000209:etiology; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011446:Prospective Studies; D011788:Quality of Life; D016037:Single-Blind Method; D011795:Surveys and Questionnaires; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D006454:Hemoglobins; D008315:Malondialdehyde; D002945:Cisplatin